Innovent Biologics Inc (6IB) — Cash Flow-to-Debt Ratio
Innovent Biologics Inc (6IB) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2023, meaning its operating cash flow of €-311.45 Million could theoretically repay 0% of its total liabilities (€7.11 Billion) in one year. Check 6IB cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Innovent Biologics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Innovent Biologics Inc across 10 annual periods. Also explore total assets of Innovent Biologics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Innovent Biologics Inc (2016–2025)
Year-by-year debt coverage analysis for Innovent Biologics Inc. For market capitalisation and broader financial context, see Innovent Biologics Inc (6IB) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.56x | €10.00 Billion | €17.99 Billion | ▲ +266.5% |
| 2024 | 0.15x | €1.29 Billion | €8.48 Billion | ▲ +731.2% |
| 2023 | 0.02x | €147.81 Million | €8.10 Billion | ▲ +106.5% |
| 2022 | -0.28x | €-1.92 Billion | €6.86 Billion | ▲ +18.3% |
| 2021 | -0.34x | €-2.02 Billion | €5.91 Billion | ▼ -240.0% |
| 2020 | -0.10x | €-307.69 Million | €3.06 Billion | ▲ +85.0% |
| 2019 | -0.67x | €-1.66 Billion | €2.47 Billion | ▼ -27.5% |
| 2018 | -0.53x | €-1.01 Billion | €1.92 Billion | ▼ -337.1% |
| 2017 | -0.12x | €-492.27 Million | €4.08 Billion | ▼ -25.5% |
| 2016 | -0.10x | €-362.99 Million | €3.77 Billion | — |